Quantum-Si Inc
NASDAQ:QSI
Quantum-Si Inc
Quantum-Si, Inc. develops a protein sequencing platform of proteomics. The company is headquartered in Guilford, Connecticut and currently employs 153 full-time employees. The company went IPO on 2020-09-04. The firm has designed and developed a hardware and software solution to provide a full end-to-end solution. The firm has developed a single molecule detection platform to enable Next Generation Protein Sequencing (NGPS), the ability to sequence proteins. The Company’s platform is comprised of the Carbon automated sample preparation instrument; the Platinum NGPS instrument’ the Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. Its Carbon instrument is an automated sample preparation instrument that is designed for use in both protein and deoxyribonucleic acid (DNA) applications. Its Platinum is designed to make the power of single-molecule detection and NGPS broadly accessible. Its Quantum-Si Cloud platform is designed to integrate a cloud-based solution into the instrument to stream data in real-time to the cloud, where analytical workflows can then interpret the data.
Quantum-Si, Inc. develops a protein sequencing platform of proteomics. The company is headquartered in Guilford, Connecticut and currently employs 153 full-time employees. The company went IPO on 2020-09-04. The firm has designed and developed a hardware and software solution to provide a full end-to-end solution. The firm has developed a single molecule detection platform to enable Next Generation Protein Sequencing (NGPS), the ability to sequence proteins. The Company’s platform is comprised of the Carbon automated sample preparation instrument; the Platinum NGPS instrument’ the Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. Its Carbon instrument is an automated sample preparation instrument that is designed for use in both protein and deoxyribonucleic acid (DNA) applications. Its Platinum is designed to make the power of single-molecule detection and NGPS broadly accessible. Its Quantum-Si Cloud platform is designed to integrate a cloud-based solution into the instrument to stream data in real-time to the cloud, where analytical workflows can then interpret the data.
Revenue Headwinds: Q3 revenue was $552,000, with ongoing capital market and NIH funding headwinds continuing to impact sales.
Placement Program: 12 new customers implemented the company’s platform through alternative acquisition models, with more than half in academic labs previously hard to access.
Proteus Milestone: The company achieved successful sequencing runs on multiple prototype Proteus systems, hitting a major 2025 R&D milestone on schedule.
Product Launches: Commercial launch of the version 4 sequencing kit occurred in early September, expanding capabilities for customers.
Cost Controls: Adjusted operating expenses decreased year-over-year, showing tight cost discipline despite ongoing investment in innovation.
Lease Termination: The company settled and terminated a costly lease in New Haven, incurring a $13.6 million expense but saving over $24 million in future operating costs.
Cash Position & Guidance: Ended Q3 with $230.5 million in cash and investments; 2025 cash use guidance raised to $103 million (from $95 million) due to the lease settlement, but underlying cash burn remains below prior targets.
Academic Traction: Placement program is broadening the installed base, especially in academia, and is expected to drive consumable sales and scientific publications.
